Actinium Pharmaceuticals, Inc.ATNMNYSE
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank7
Studio
Year-over-Year Change

Year-over-year research & development expense growth

Percentile
P7
Near historical low
vs 3Y Ago
-2.5x
Contraction
Streak
1 yr
Consecutive declineDecelerating
PeriodValue
2024-22.30%
202367.15%
202232.15%
20218.84%
2020-2.81%
2019-3.19%
2018-3.42%
20171.14%
201631.47%
20158.52%